tetrazine-based small-molecule radioligand (MabVax Therapeutics/Memorial Sloan-Kettering Cancer Center/City University of New York)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Nametetrazine-based small-molecule radioligand (MabVax Therapeutics/Memorial Sloan-Kettering Cancer Center/City University of New York)
Drug Alias Name177Lu-DOTA-PEG7-Tz177Lu-DOTA-PEG7-tetrazineFluorine-18-JM-04418F-JM-044JM-044-[18F]
ClassificationSmall moleculesRadiation-emitting products > Radioactive therapeutic agent
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMabvax Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMabvax Therapeutics IncCity University Of New YorkMemorial Sloan Kettering Cancer Center
Active IndicationsN/A
Inactive IndicationsPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A